Adage Capital Partners GP L.L.C. Sells 5,135,190 Shares of Compass Therapeutics, Inc. (NASDAQ:CMPX)

Adage Capital Partners GP L.L.C. lessened its holdings in shares of Compass Therapeutics, Inc. (NASDAQ:CMPX - Free Report) by 46.1% in the 4th quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The firm owned 5,994,810 shares of the company's stock after selling 5,135,190 shares during the period. Adage Capital Partners GP L.L.C. owned about 4.36% of Compass Therapeutics worth $8,692,000 at the end of the most recent reporting period.

Several other hedge funds also recently bought and sold shares of the business. Rock Springs Capital Management LP grew its stake in shares of Compass Therapeutics by 2.7% during the 4th quarter. Rock Springs Capital Management LP now owns 5,779,575 shares of the company's stock worth $8,380,000 after purchasing an additional 150,336 shares during the period. Geode Capital Management LLC lifted its position in Compass Therapeutics by 1.1% in the fourth quarter. Geode Capital Management LLC now owns 2,334,171 shares of the company's stock valued at $3,386,000 after buying an additional 24,393 shares during the last quarter. SG Americas Securities LLC raised its holdings in shares of Compass Therapeutics by 921.6% in the 4th quarter. SG Americas Securities LLC now owns 395,017 shares of the company's stock valued at $573,000 after buying an additional 356,352 shares during the period. Renaissance Technologies LLC lifted its holdings in Compass Therapeutics by 25.2% during the 4th quarter. Renaissance Technologies LLC now owns 278,600 shares of the company's stock worth $404,000 after buying an additional 56,000 shares in the last quarter. Finally, JPMorgan Chase & Co. grew its position in shares of Compass Therapeutics by 512.5% during the fourth quarter. JPMorgan Chase & Co. now owns 272,328 shares of the company's stock worth $395,000 after buying an additional 227,864 shares in the last quarter. Institutional investors own 68.43% of the company's stock.

Wall Street Analyst Weigh In

A number of equities analysts have recently issued reports on the stock. Piper Sandler began coverage on shares of Compass Therapeutics in a research report on Wednesday, February 19th. They set an "overweight" rating and a $12.00 target price on the stock. HC Wainwright restated a "buy" rating and issued a $24.00 price target on shares of Compass Therapeutics in a research report on Monday, April 21st. Leerink Partners raised Compass Therapeutics from a "market perform" rating to an "outperform" rating and raised their price target for the stock from $4.00 to $6.00 in a research report on Wednesday, April 2nd. Guggenheim reiterated a "buy" rating on shares of Compass Therapeutics in a report on Tuesday, April 22nd. Finally, Jefferies Financial Group boosted their target price on Compass Therapeutics from $7.00 to $8.00 and gave the stock a "buy" rating in a report on Monday, February 10th. Eight analysts have rated the stock with a buy rating and one has issued a strong buy rating to the stock. According to data from MarketBeat.com, the company currently has a consensus rating of "Buy" and an average target price of $13.38.

Insider Buying and Selling

In other Compass Therapeutics news, Director Carl L. Gordon sold 3,571,428 shares of the stock in a transaction that occurred on Wednesday, April 9th. The stock was sold at an average price of $1.59, for a total value of $5,678,570.52. The sale was disclosed in a document filed with the SEC, which is available at this hyperlink. Also, insider Jonathan Anderman bought 20,000 shares of the business's stock in a transaction that occurred on Monday, April 7th. The shares were bought at an average cost of $1.54 per share, for a total transaction of $30,800.00. Following the transaction, the insider now owns 21,000 shares of the company's stock, valued at $32,340. The trade was a 2,000.00 % increase in their ownership of the stock. The disclosure for this purchase can be found here. 28.50% of the stock is owned by corporate insiders.

Compass Therapeutics Stock Performance

NASDAQ CMPX traded up $0.07 on Friday, reaching $1.89. The company had a trading volume of 732,940 shares, compared to its average volume of 884,347. The firm has a market capitalization of $261.35 million, a price-to-earnings ratio of -5.11 and a beta of 1.40. Compass Therapeutics, Inc. has a 1-year low of $0.77 and a 1-year high of $4.08. The company's fifty day moving average is $2.10 and its 200-day moving average is $2.10.

Compass Therapeutics (NASDAQ:CMPX - Get Free Report) last posted its quarterly earnings results on Thursday, February 27th. The company reported ($0.11) earnings per share for the quarter, missing analysts' consensus estimates of ($0.10) by ($0.01). On average, research analysts forecast that Compass Therapeutics, Inc. will post -0.36 earnings per share for the current year.

About Compass Therapeutics

Compass Therapeutics, Inc, a clinical-stage oncology-focused biopharmaceutical company, engages in developing antibody-based therapeutics to treat various human diseases in the United States. The company's lead product candidates include CTX-009, a bispecific antibody that blocks Delta-like ligand 4 a ligand of Notch-1, and vascular endothelial growth factor A signaling pathways, which are critical to angiogenesis and tumor vascularization; and CTX-471, an IgG4 monoclonal antibody that is an agonist of CD137, a key co-stimulatory receptor on immune cells.